Yuxian Bai
YOU?
Author Swipe
View article: Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial
Fruquintinib plus sintilimab in previously bevacizumab-treated, pMMR/MSS refractory metastatic colorectal cancer: a phase 2 clinical trial Open
View article: Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study
Analysis of common treatment-related adverse events of donafenib and its correlation with efficacy: exploratory analysis of the ZGDH3 study Open
NCT02645981.
View article: Development and Clinical Trial of M701, an Anti-EpCAM × Anti-CD3 Bispecific Antibody: A Targeted Intraperitoneal Therapy for Malignant Ascites Stemming from Advanced Solid Tumors
Development and Clinical Trial of M701, an Anti-EpCAM × Anti-CD3 Bispecific Antibody: A Targeted Intraperitoneal Therapy for Malignant Ascites Stemming from Advanced Solid Tumors Open
Background Malignant ascites (MA) is one of the major complications in advanced epithelial cancer patients and is associated with poor prognosis, poor quality of life, and severe symptoms. No efficient medicine is available for treating MA…
View article: Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO Open
Clinically meaningful efficacy of fruquintinib was maintained in a global patient population with less pretreated mCRC than the FRESCO-2 ITT population, with no new safety signals, demonstrating efficacy regardless of prior treatment lines.
View article: The extracts of small-leaved kudingcha as potential modulators of β-cells for the therapy of type 2 diabetes mellitus
The extracts of small-leaved kudingcha as potential modulators of β-cells for the therapy of type 2 diabetes mellitus Open
Small-leaved Kudingcha (SLK), a unique variety of tea, has blood sugar-lowering effect. However, the underlying molecular mechanisms of lowering blood sugar is still unclear. Here, the crude extract of SLK and its four fractions of petrole…
View article: Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study
Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study Open
PURPOSE The phase III randomized open-label LEAP-015 study (ClinicalTrials.gov identifier: NCT04662710 ) evaluated first-line lenvatinib plus pembrolizumab and chemotherapy versus chemotherapy for advanced metastatic gastroesophageal adeno…
View article: First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial
First-line treatment of anti-EGFR monoclonal antibody cetuximab β plus FOLFIRI versus FOLFIRI alone in Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer: a randomized, phase 3 trial Open
View article: Involvement of the miR-210-3P/Gbp3 Axis in NLRP3 Inflammasome modulation by Royal Jelly Acid in ulcerative colitis therapy
Involvement of the miR-210-3P/Gbp3 Axis in NLRP3 Inflammasome modulation by Royal Jelly Acid in ulcerative colitis therapy Open
View article: First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study
First-Line Pembrolizumab Plus Chemotherapy for HER2-Negative Advanced Gastric Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-859 Study Open
View article: Effect of surgery on overall survival and cancer-specific survival in patients with primary HCC: A study based on PSM in the SEER cohort
Effect of surgery on overall survival and cancer-specific survival in patients with primary HCC: A study based on PSM in the SEER cohort Open
This study was designed to assess the effects of surgery method on overall survival (OS) and cancer-specific survival (CSS) in patients with hepatocellular carcinoma (HCC). This is a retrospective study. Patients diagnosed with primary HCC…
View article: Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma
Phase 2 study of serplulimab with the bevacizumab biosimilar HLX04 in the first-line treatment of advanced hepatocellular carcinoma Open
Serplulimab combination therapy with HLX04 showed a manageable safety profile as well as preliminary efficacy in patients with advanced HCC in the first-line setting.
View article: Phase Ib/II Study of the CEND-1 (Targeting αV-Integrin and Neuropilin-1) with nab-Paclitaxel/Gemcitabine in First-Line Treatment of Metastatic Pancreatic Cancer
Phase Ib/II Study of the CEND-1 (Targeting αV-Integrin and Neuropilin-1) with nab-Paclitaxel/Gemcitabine in First-Line Treatment of Metastatic Pancreatic Cancer Open
View article: Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer Open
View article: Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial
Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial Open
Liposomal irinotecan has shown promising antitumor activity in patients with advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) who have undergone prior gemcitabine-based therapies. This randomized, double-blind, parallel-contr…
View article: Pembrolizumab in HER2-Positive Gastric Cancer
Pembrolizumab in HER2-Positive Gastric Cancer Open
View article: SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer
SAFFRON-104: a phase Ib/II study of sitravatinib alone or with tislelizumab in advanced hepatocellular carcinoma and gastric cancer/gastroesophageal junction cancer Open
BACKGROUND: Sitravatinib is a spectrum-selective tyrosine kinase inhibitor targeting TAM (TYRO3, AXL, MER), VEGFR-2, KIT, and MET. SAFFRON-104 (NCT03941873) was a multicohort phase Ib/II study investigating sitravatinib with/without tislel…
View article: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first line treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma: RATIONALE-305 randomised, double blind, phase 3 trial Open
Objective To evaluate the efficacy and safety of tislelizumab added to chemotherapy as first line (primary) treatment for advanced gastric or gastro-oesophageal junction adenocarcinoma compared with placebo plus chemotherapy. Design Random…
View article: Anti‐PD‐L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy‐refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study
Anti‐PD‐L1 antibody TQB2450 combined with tyrosine kinase receptor inhibitor AL2846 for immunotherapy‐refractory advanced hepatocellular carcinoma and esophageal squamous cell carcinoma: A prospective phase 1b cohort study Open
Background Effective systemic therapy remains limited for advanced esophageal squamous cell carcinoma (ESCC) and hepatocellular carcinoma (HCC), particularly after prior failed treatment with immune checkpoint inhibitors (ICIs). Theoretica…
View article: Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study
Efficacy, safety and genomic analysis of SCT200, an anti-EGFR monoclonal antibody, in patients with fluorouracil, irinotecan and oxaliplatin refractory RAS and BRAF wild-type metastatic colorectal cancer: a phase Ⅱ study Open
View article: Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer Open
Importance Gastric and gastroesophageal junction cancers are diagnosed in more than 1 million people worldwide annually, and few effective treatments are available. Sintilimab, a recombinant human IgG4 monoclonal antibody that binds to pro…
View article: Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study
Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study Open
View article: The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial
The efficacy and safety of cadonilimab combined with lenvatinib for first-line treatment of advanced hepatocellular carcinoma (COMPASSION-08): a phase Ib/II single-arm clinical trial Open
Purpose This multicenter, open-label, phase Ib/II study aimed to assess the efficacy and safety of cadonilimab, a humanized, tetravalent, bispecific antibody plus lenvatinib in first-line treatment of advanced hepatocellular carcinoma (aHC…
View article: Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma
Tislelizumab vs Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Open
Importance Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality, and additional first-line treatments are needed. The programmed cell death protein 1 inhibitor tislelizumab demonstrated efficacy and a tolerable saf…
View article: 136P Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158
136P Pembrolizumab in patients of Chinese descent with microsatellite instability-high/mismatch repair deficient advanced solid tumors: KEYNOTE-158 Open
View article: LBA80 Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study
LBA80 Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Final analysis results of the RATIONALE-305 study Open
View article: 948P Phase (Ph) I/II study of sitravatinib (Sitra) alone or with tislelizumab (TIS) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/GEJC)
948P Phase (Ph) I/II study of sitravatinib (Sitra) alone or with tislelizumab (TIS) in advanced hepatocellular carcinoma (HCC) and gastric/gastroesophageal junction cancer (GC/GEJC) Open
View article: 1519P Fruquintinib plus sintilimab in patients (pts) with either treatment-naïve or previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results from a multicenter, single-arm phase II study
1519P Fruquintinib plus sintilimab in patients (pts) with either treatment-naïve or previously treated advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Results from a multicenter, single-arm phase II study Open
View article: 1511O Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study
1511O Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: Survival results from the phase III, randomized, double-blind, placebo-controlled KEYNOTE-811 study Open
View article: 611P SHR-1701 in combination with BP102 and XELOX as first-line (1L) treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Data from a phase II/III study
611P SHR-1701 in combination with BP102 and XELOX as first-line (1L) treatment for patients (pts) with unresectable metastatic colorectal cancer (mCRC): Data from a phase II/III study Open
View article: Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer
Nimotuzumab Plus Gemcitabine for K-Ras Wild-Type Locally Advanced or Metastatic Pancreatic Cancer Open
K-Ras pancreatic cancers benefit overall survival in phase 3 NOTABLE study.